Become A Featured Company

Seasoned Business Leaders Join Forces to Disrupt Psychedelics Sector

Ryan Allway

December 7th, 2021

News

Mycotopia Therapies Inc. (OTC Pink: TPIA), a biopharmaceutical company focused on medicinal psychedelics research, technology, and development, recently announced that it has reached a definitive agreement to merge with botanical psilocybin pioneer Ei.Ventures. The two companies plan to combine their resources to produce FDA-approved plant-derived psychoactive therapeutic treatment options, as well as non-psychoactive nutritional supplements and related products, to meet global mental healthcare needs.

“Psilocybin and other psychedelic medicines have tremendous potential to improve the mental health of many people who have given up hope,” says Mycotopia Therapies CEO Ben Kaplan. “Our passion has been focused on how Psilocybin and other psychedelic medicines are changing the lives of many individuals struggling with anxiety, depression, PTSD, opioid use disorder and other harmful addictions. Joining forces with Ei.Ventures presents a unique solution with the potential to accelerate our results. We are excited to work with the Ei.Ventures team in an attempt to impact mental health where Big Pharma has run out of options.”

The deal should be completed in the first quarter of 2022. At that time, David Nikzad and Jason A. Hobson will be appointed as officers and directors of the company, and the company’s name will be changed to PSLY.COM to better reflect its future operations. The company intends to trade under the symbol PSLY. The final management team will bring experience in the public and private markets with combined investments in over 100 companies and leadership in the nascent psychedelics movement.

The flagship botanical psilocybin-based product from Ei.Ventures, Psilly, is a pre-clinical, psilocybin-based botanical blend of whole plant and fungi designed to facilitate the “Entourage Effect”. The Entourage Effect, according to researchers, may be crucial to psilocybin’s therapeutic properties. It’s the result of a synergistic interaction between two or more compounds present in the same plant. Similar to how different strains of cannabis have varying impacts on the end-user, psilocybin mushrooms are now thought to have the same effect. The two companies want to finish pre-clinical and phase one trials with the FDA and then launch the innovative product into markets where it would be legal.

For its part, Mycotopia Therapies is dedicated to the creation, testing, and marketing of new treatments based on naturally occurring psilocybin. The company focuses on mushroom and psychedelic potential, conducting much of its research in Jamaica, where psilocybin is allowed. It’s working with one of the largest cannabis labs in the Netherlands to jointly create psychedelic medicine and plans to open psilocybin and ketamine clinics in Jamaica under the direction of a licensed clinical psychologist.

Instead of single-molecule synthetic pharmaceuticals, PSLY.COM will concentrate their efforts on developing fungal and plant-based Botanical Psychedelic API and Therapeutics, distinguishing it from practically every other firm in the space that is producing synthetic versions of psilocybin in their laboratories. Ei.Ventures holds the patent for the extraction technique of three botanical potential API constituents, Psilocybin, DMT, and MDMA, in its patent portfolio. PSLY.COM intends to continue developing this API and file a Drug Master File with the FDA, which will allow it to potentially offer the API to other companies while protecting its intellectual property.

“I am excited by the amount of wisdom these two companies bring together,” says Ei. Ventures Founder & Chaiman David Nikzad. “Everyone in these companies has a background in public markets, a decade plus in cannabis, and lawyers that have been involved in cannabis legislation, as well as start-ups, and heavily compliance-oriented businesses. We were the first to work on legally-compliant CBD products, and we were the first to work on a commercial Ayurvedic spa in the US built around plant medicine.”

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading